Filters
clear all
Filters
Topics
Industry
Type
Brand
Enlyte Article

Release of Generic Medications for Workers' Comp in 2022

1 MIN READ

Next year twenty-eight drugs relevant to workers’ compensation are expected to become available as generics. These formulations will be made available once the original drug manufacturer’s brand name period of exclusivity has expired.

Enlyte Article

FDA Approves Combination NSAID/Opioid Seglentis

2 MIN READ

On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).

Enlyte Article

FDA Approves Combination NSAID/Opioid Seglentis

2 MIN READ

On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Mitchell Virtual Event

2021 mPower Virtual Conference

On-Demand

The Mitchell | Genex | Coventry team looks forward to connecting with you at the 2021 mPower Conference, taking place virtually October 12–14, 2021.

Enlyte Article

Opioid Reduction Success

2 MIN READ

Enlyte Article

Opioid Reduction Success

2 MIN READ

Enlyte Blog

As crises pile on, U.S. hospitals brace for a harrowing winter

5 MIN READ

The coronavirus pandemic is perhaps best depicted by the voids it carves rather than by what it yields. The disappearances of handshakes, rush hour traffic, and sellout crowds at sporting events reveal the outlines of a nation transformed.